<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7303642\results\search\disease\results.xml">
  <result pre="italic;} J Am Acad DermatolJ. Am. Acad. DermatolJournal of the" exact="American" post="Academy of Dermatology0190-96221097-6787by the American Academy of Dermatology, Inc."/>
  <result pre="Am. Acad. DermatolJournal of the American Academy of Dermatology0190-96221097-6787by the" exact="American" post="Academy of Dermatology, Inc. pmcid: 7303642S0190-9622(20)31149-X doi: 10.1016/j.jaad.2020.06.051 :"/>
  <result pre="Pasteur, 319, Boston, MA 02115. pmc-release: 2020-6-6ppub: 2020-10epub: 2020-6-683411501159accepted: 2020-6-10(C)" exact="American" post="Academy of Dermatology, Inc., 2020Since January 2020 Elsevier has"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="the COVID-19 resource centre remains active. Abstract Dermatologists treating immune-mediated" exact="skin disease" post="must now contend with the uncertainties associated with immunosuppressive"/>
  <result pre="COVID-19 resource centre remains active. Abstract Dermatologists treating immune-mediated skin" exact="disease" post="must now contend with the uncertainties associated with immunosuppressive"/>
  <result pre="associated with immunosuppressive use in the context of the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk"/>
  <result pre="with immunosuppressive use in the context of the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of"/>
  <result pre="immunosuppressive use in the context of the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection"/>
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of" exact="infection" post="with many commonly used immunosuppressive agents remains low, direct"/>
  <result pre="direct data evaluating the safety of such agents in coronavirus" exact="disease" post="2019 (COVID-19) are scarce. This article reviews and offers"/>
  <result pre="this article is to help providers minimize the risk of" exact="disease" post="flares while simultaneously minimizing the risk of iatrogenic harm"/>
  <result pre="risk of iatrogenic harm during an evolving pandemic. Key words" exact="autoimmune disease" post="COVID-19 dermatology-rheumatology immunosuppression immunosuppressive therapy medical dermatology SARS-CoV-2 Abbreviations"/>
  <result pre="of iatrogenic harm during an evolving pandemic. Key words autoimmune" exact="disease" post="COVID-19 dermatology-rheumatology immunosuppression immunosuppressive therapy medical dermatology SARS-CoV-2 Abbreviations"/>
  <result pre="medical dermatology SARS-CoV-2 Abbreviations used CI, confidence interval COVID-19, coronavirus" exact="disease" post="2019 IL, interleukin MERS, Middle East respiratory syndrome OR,"/>
  <result pre="interval COVID-19, coronavirus disease 2019 IL, interleukin MERS, Middle East" exact="respiratory" post="syndrome OR, odds ratio RR, relative risk SARS, severe"/>
  <result pre="COVID-19, coronavirus disease 2019 IL, interleukin MERS, Middle East respiratory" exact="syndrome" post="OR, odds ratio RR, relative risk SARS, severe acute"/>
  <result pre="respiratory syndrome OR, odds ratio RR, relative risk SARS, severe" exact="acute" post="respiratory syndrome SARS-CoV-2, severe acute respiratory syndrome coronavirus 2"/>
  <result pre="syndrome OR, odds ratio RR, relative risk SARS, severe acute" exact="respiratory" post="syndrome SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 TNF,"/>
  <result pre="OR, odds ratio RR, relative risk SARS, severe acute respiratory" exact="syndrome" post="SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 TNF, tumor"/>
  <result pre="RR, relative risk SARS, severe acute respiratory syndrome SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 TNF, tumor necrosis factor URI,"/>
  <result pre="relative risk SARS, severe acute respiratory syndrome SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 TNF, tumor necrosis factor URI, upper"/>
  <result pre="risk SARS, severe acute respiratory syndrome SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 TNF, tumor necrosis factor URI, upper respiratory"/>
  <result pre="respiratory syndrome SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 TNF," exact="tumor" post="necrosis factor URI, upper respiratory tract VTE, venous thromboembolism"/>
  <result pre="acute respiratory syndrome coronavirus 2 TNF, tumor necrosis factor URI," exact="upper" post="respiratory tract VTE, venous thromboembolism Capsule Summary â€¢This article"/>
  <result pre="respiratory syndrome coronavirus 2 TNF, tumor necrosis factor URI, upper" exact="respiratory" post="tract VTE, venous thromboembolism Capsule Summary â€¢This article adds"/>
  <result pre="2 TNF, tumor necrosis factor URI, upper respiratory tract VTE," exact="venous thromboembolism" post="Capsule Summary â€¢This article adds to the limited literature"/>
  <result pre="VTE, venous thromboembolism Capsule Summary â€¢This article adds to the" exact="limited" post="literature on coronavirus disease 2019 (COVID-19) and immunosuppression. It"/>
  <result pre="Summary â€¢This article adds to the limited literature on coronavirus" exact="disease" post="2019 (COVID-19) and immunosuppression. It provides expert opinion based"/>
  <result pre="existing regimens of their patients. This article will examine relevant" exact="systemic" post="drug safety data obtained from clinical trials, registries, and"/>
  <result pre="uncertainty. Baseline risk in immune-mediated dermatologic disorders Evaluating the baseline" exact="infection" post="risk of patients isÂ an important aspect of risk"/>
  <result pre="important aspect of risk stratification. Several immune-mediated conditions, such as" exact="psoriasis" post="and lupus, are associated with increased infection risk irrespective"/>
  <result pre="conditions, such as psoriasis and lupus, are associated with increased" exact="infection" post="risk irrespective of exposure to immunomodulatory agents.1,2 Many of"/>
  <result pre="associated with comorbidities known to predict poor outcomes in COVID-19" exact="infection" post="(eg, diabetes and obesity in patients with psoriasis, asthma"/>
  <result pre="comorbidities known to predict poor outcomes in COVID-19 infection (eg," exact="diabetes" post="and obesity in patients with psoriasis, asthma in patients"/>
  <result pre="known to predict poor outcomes in COVID-19 infection (eg, diabetes" exact="and obesity" post="in patients with psoriasis, asthma in patients with atopic"/>
  <result pre="to predict poor outcomes in COVID-19 infection (eg, diabetes and" exact="obesity" post="in patients with psoriasis, asthma in patients with atopic"/>
  <result pre="COVID-19 infection (eg, diabetes and obesity in patients with psoriasis," exact="asthma" post="in patients with atopic dermatitis, and interstitial lung disease"/>
  <result pre="and obesity in patients with psoriasis, asthma in patients with" exact="atopic dermatitis," post="and interstitial lung disease with connective tissue disorders).3 Each"/>
  <result pre="patients with psoriasis, asthma in patients with atopic dermatitis, and" exact="interstitial lung disease" post="with connective tissue disorders).3 Each patient presents a unique"/>
  <result pre="with psoriasis, asthma in patients with atopic dermatitis, and interstitial" exact="lung disease" post="with connective tissue disorders).3 Each patient presents a unique"/>
  <result pre="psoriasis, asthma in patients with atopic dermatitis, and interstitial lung" exact="disease" post="with connective tissue disorders).3 Each patient presents a unique"/>
  <result pre="decision-making process concerning immunosuppressive and immunomodulatory therapy during the coronavirus" exact="disease" post="2019 pandemic 1.The severity of the underlying disease, with"/>
  <result pre="information. Learning from the past COVID-19 appears to follow a" exact="disease" post="course similar to previous highly pathogenic coronavirus infections (ie,"/>
  <result pre="follow a disease course similar to previous highly pathogenic coronavirus" exact="infections" post="(ie, Middle East respiratory syndrome [MERS] and severe acute"/>
  <result pre="similar to previous highly pathogenic coronavirus infections (ie, Middle East" exact="respiratory" post="syndrome [MERS] and severe acute respiratory syndrome [SARS]), with"/>
  <result pre="to previous highly pathogenic coronavirus infections (ie, Middle East respiratory" exact="syndrome" post="[MERS] and severe acute respiratory syndrome [SARS]), with up"/>
  <result pre="coronavirus infections (ie, Middle East respiratory syndrome [MERS] and severe" exact="acute" post="respiratory syndrome [SARS]), with up to 20% of hospitalized"/>
  <result pre="infections (ie, Middle East respiratory syndrome [MERS] and severe acute" exact="respiratory" post="syndrome [SARS]), with up to 20% of hospitalized patients"/>
  <result pre="(ie, Middle East respiratory syndrome [MERS] and severe acute respiratory" exact="syndrome" post="[SARS]), with up to 20% of hospitalized patients progressing"/>
  <result pre="up to 20% of hospitalized patients progressing to potentially fatal" exact="acute" post="respiratory distress syndrome.4 Risk factors for poor outcomes during"/>
  <result pre="to 20% of hospitalized patients progressing to potentially fatal acute" exact="respiratory" post="distress syndrome.4 Risk factors for poor outcomes during the"/>
  <result pre="age and the presence of comorbidities such as obesity, diabetes," exact="heart" post="disease, lung disease, and renal disease. Immunosuppression alone was"/>
  <result pre="the presence of comorbidities such as obesity, diabetes, heart disease," exact="lung disease," post="and renal disease. Immunosuppression alone was not identified as"/>
  <result pre="of comorbidities such as obesity, diabetes, heart disease, lung disease," exact="and renal disease." post="Immunosuppression alone was not identified as a significant risk"/>
  <result pre="comorbidities such as obesity, diabetes, heart disease, lung disease, and" exact="renal disease." post="Immunosuppression alone was not identified as a significant risk"/>
  <result pre="alone was not identified as a significant risk factor for" exact="primary" post="infection or death,5,6 and several milder or attenuated cases"/>
  <result pre="was not identified as a significant risk factor for primary" exact="infection" post="or death,5,6 and several milder or attenuated cases of"/>
  <result pre="infection or death,5,6 and several milder or attenuated cases of" exact="infection" post="were reported in immunosuppressed populations.7,8 Corroborating this, a National"/>
  <result pre="animal study showed that macaques immunosuppressed with cyclophosphamide had significantly" exact="lower" post="rates of lung pathology despite active MERS-CoV infection.9 It"/>
  <result pre="despite active MERS-CoV infection.9 It has been hypothesized that severe" exact="pulmonary" post="involvement is likely secondary to an excessive inflammatory response,"/>
  <result pre="It has been hypothesized that severe pulmonary involvement is likely" exact="secondary" post="to an excessive inflammatory response, characterized by macrophage hyperactivation"/>
  <result pre="data and relevant trial data are presented below. Data regarding" exact="infection" post="risk and complications of immunosuppressive and immunomodulatory agents Glucocorticoids"/>
  <result pre="and complications of immunosuppressive and immunomodulatory agents Glucocorticoids Evidence linking" exact="systemic" post="corticosteroids to increased infection risk comes from a meta-analysis"/>
  <result pre="and immunomodulatory agents Glucocorticoids Evidence linking systemic corticosteroids to increased" exact="infection" post="risk comes from a meta-analysis of 71 clinical trials,"/>
  <result pre="71 clinical trials, which found an increased overall rate of" exact="infection" post="in patients receiving systemic corticosteroids (relative risk [RR], 1.6;"/>
  <result pre="found an increased overall rate of infection in patients receiving" exact="systemic" post="corticosteroids (relative risk [RR], 1.6; 95% confidence interval [CI],"/>
  <result pre="Corrona registry (Corrona, LLC, Waltham, MA) also found increased overall" exact="infection" post="risk with prednisone &amp;gt;10Â mg/d in patients with rheumatoid"/>
  <result pre="overall infection risk with prednisone &amp;gt;10Â mg/d in patients with" exact="rheumatoid arthritis" post="(incidence rate ratio, 1.30; 95% CI, 1.1-1.5).13 Therapeutic potential"/>
  <result pre="infection risk with prednisone &amp;gt;10Â mg/d in patients with rheumatoid" exact="arthritis" post="(incidence rate ratio, 1.30; 95% CI, 1.1-1.5).13 Therapeutic potential"/>
  <result pre="1.1-1.5).13 Therapeutic potential in COVID-19 Data evaluating the use of" exact="systemic" post="corticosteroids in COVID-19 are limited. Recently, the preliminary results"/>
  <result pre="conflicting and many studies have revealed no mortality benefit, delayed" exact="viral" post="clearance, and evidence for harm.15, 16, 17 A similar"/>
  <result pre="benefit and potential for harm has been noted in other" exact="viral" post="pneumonias, including influenza and respiratory syncytial virus.18,19 Conclusions There"/>
  <result pre="has been noted in other viral pneumonias, including influenza and" exact="respiratory" post="syncytial virus.18,19 Conclusions There is evidence for harm without"/>
  <result pre="is evidence for harm without a clear mortality benefit when" exact="systemic" post="corticosteroids have been used to treat MERS and SARS-associated"/>
  <result pre="pneumonia. Existing safety data also indicates that daily doses of" exact="systemic" post="corticosteroids &amp;gt;10 mg of prednisone equivalent are associated with"/>
  <result pre="&amp;gt;10 mg of prednisone equivalent are associated with an increased" exact="susceptibility to" post="overall infection. Recently however, preliminary evidence from a large"/>
  <result pre="needed to define the optimal use and potential complications of" exact="systemic" post="corticosteroid use in the setting of COVID-19. Methotrexate In"/>
  <result pre="the setting of COVID-19. Methotrexate In clinical trials, methotrexate increased" exact="infection" post="risk in patients with rheumatoid arthritis (risk ratio, 1.25;"/>
  <result pre="In clinical trials, methotrexate increased infection risk in patients with" exact="rheumatoid arthritis" post="(risk ratio, 1.25; 95% CI, 1.01-1.56), compared with placebo,"/>
  <result pre="clinical trials, methotrexate increased infection risk in patients with rheumatoid" exact="arthritis" post="(risk ratio, 1.25; 95% CI, 1.01-1.56), compared with placebo,"/>
  <result pre="but not in those with other immune-mediated conditions, including psoriasis," exact="psoriatic arthritis," post="ankylosing spondylitis, and scleroderma.20 Robust data for adverse events"/>
  <result pre="in those with other immune-mediated conditions, including psoriasis, psoriatic arthritis," exact="ankylosing spondylitis," post="and scleroderma.20 Robust data for adverse events related to"/>
  <result pre="evaluating the efficacy of low-dose methotrexate for the treatment of" exact="atherosclerosis" post="in patients with cardiovascular disease. Mild infections were slightly"/>
  <result pre="low-dose methotrexate for the treatment of atherosclerosis in patients with" exact="cardiovascular disease." post="Mild infections were slightly increased (hazard ratio, 1.15; 95%"/>
  <result pre="the treatment of atherosclerosis in patients with cardiovascular disease. Mild" exact="infections" post="were slightly increased (hazard ratio, 1.15; 95% CI, 1.01-1.30),"/>
  <result pre="CI, 1.01-1.30), but there was no statistically significant increase in" exact="upper" post="respiratory tract (URI) or influenza infections.21 Conclusions A modestly"/>
  <result pre="1.01-1.30), but there was no statistically significant increase in upper" exact="respiratory" post="tract (URI) or influenza infections.21 Conclusions A modestly increased"/>
  <result pre="(URI) or influenza infections.21 Conclusions A modestly increased risk of" exact="infection" post="associated with methotrexate has been suggested in some studies."/>
  <result pre="for their immunomodulatory properties, antimalarials have not been associated with" exact="infectious" post="complications in systemic autoimmune disease,22,23 and some studies even"/>
  <result pre="properties, antimalarials have not been associated with infectious complications in" exact="systemic" post="autoimmune disease,22,23 and some studies even suggest their use"/>
  <result pre="antimalarials have not been associated with infectious complications in systemic" exact="autoimmune" post="disease,22,23 and some studies even suggest their use may"/>
  <result pre="some studies even suggest their use may help prevent serious" exact="infections" post="in systemic lupus erythematosus.2 Therapeutic potential in COVID-19 Antimalarial"/>
  <result pre="even suggest their use may help prevent serious infections in" exact="systemic" post="lupus erythematosus.2 Therapeutic potential in COVID-19 Antimalarial drugs were"/>
  <result pre="suggest their use may help prevent serious infections in systemic" exact="lupus" post="erythematosus.2 Therapeutic potential in COVID-19 Antimalarial drugs were at"/>
  <result pre="30 Conclusions The current data show no significant risk of" exact="infection" post="or infectious complications when antimalarials are used for the"/>
  <result pre="The current data show no significant risk of infection or" exact="infectious" post="complications when antimalarials are used for the treatment of"/>
  <result pre="complications when antimalarials are used for the treatment of immune-mediated" exact="disease" post="and therefore suggest low potential for harm in COVID-19"/>
  <result pre="Schneeweiss etÂ al32 examined the 6-month risk of serious and" exact="opportunistic infections" post="in patients with atopic dermatitis. Compared with methotrexate, cyclosporine"/>
  <result pre="etÂ al32 examined the 6-month risk of serious and opportunistic" exact="infections" post="in patients with atopic dermatitis. Compared with methotrexate, cyclosporine"/>
  <result pre="6-month risk of serious and opportunistic infections in patients with" exact="atopic dermatitis." post="Compared with methotrexate, cyclosporine A had a 58% higher"/>
  <result pre="methotrexate, cyclosporine A had a 58% higher risk of overall" exact="infection" post="(adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same"/>
  <result pre="CI, 1.17-2.15). In the same study, azathioprine had double the" exact="infection" post="risk (RR, 1.78; 95% CI, 0.98-3.25), whereas mycophenolate mofetil"/>
  <result pre="3.31; 95% CI, 1.94-5.64). A separate study comparing patients with" exact="systemic" post="lupus erythematosus newly treated with mycophenolate mofetil or azathioprine"/>
  <result pre="95% CI, 1.94-5.64). A separate study comparing patients with systemic" exact="lupus erythematosus" post="newly treated with mycophenolate mofetil or azathioprine found no"/>
  <result pre="rates of serious infections.33 Studies that examined the incidence of" exact="viral" post="infections found that herpes zoster virus infections are increased"/>
  <result pre="of serious infections.33 Studies that examined the incidence of viral" exact="infections" post="found that herpes zoster virus infections are increased with"/>
  <result pre="Studies that examined the incidence of viral infections found that" exact="herpes zoster" post="virus infections are increased with azathioprine34,35 and that cytomegalovirus"/>
  <result pre="that examined the incidence of viral infections found that herpes" exact="zoster" post="virus infections are increased with azathioprine34,35 and that cytomegalovirus"/>
  <result pre="the incidence of viral infections found that herpes zoster virus" exact="infections" post="are increased with azathioprine34,35 and that cytomegalovirus infections are"/>
  <result pre="zoster virus infections are increased with azathioprine34,35 and that cytomegalovirus" exact="infections" post="are increased with mycophenolate mofetil,36 although the latter appears"/>
  <result pre="increased with mycophenolate mofetil,36 although the latter appears to be" exact="limited" post="to patients who have received a transplant. Therapeutic potential"/>
  <result pre="Azathioprine, mycophenolate mofetil, and cyclosporine A increase the risk of" exact="infection" post="relative to reference agents such as methotrexate, warranting increased"/>
  <result pre="therapy. Apremilast Long-term safety data from open-label extension studies in" exact="psoriasis" post="and psoriatic arthritis do not show an increased risk"/>
  <result pre="Long-term safety data from open-label extension studies in psoriasis and" exact="psoriatic arthritis" post="do not show an increased risk of serious infections"/>
  <result pre="safety data from open-label extension studies in psoriasis and psoriatic" exact="arthritis" post="do not show an increased risk of serious infections"/>
  <result pre="psoriatic arthritis do not show an increased risk of serious" exact="infections" post="compared with placebo.40,41 Similarly, URI and nasopharyngitis rates were"/>
  <result pre="risk of serious infections compared with placebo.40,41 Similarly, URI and" exact="nasopharyngitis" post="rates were comparable in the placebo-controlled phases of these"/>
  <result pre="studies. Conclusions The available data suggest a low risk of" exact="infection" post="associated with the use of apremilast and, therefore, low"/>
  <result pre="kinase (JAK) inhibitors comes from the use of tofacitinib in" exact="rheumatoid arthritis." post="Analysis of the most recent tofacitinib data from randomized"/>
  <result pre="data from randomized controlled trials and long-term extension studies in" exact="rheumatoid arthritis" post="reveals serious infection rates of 2.4 per 100 patient-years,42"/>
  <result pre="from randomized controlled trials and long-term extension studies in rheumatoid" exact="arthritis" post="reveals serious infection rates of 2.4 per 100 patient-years,42"/>
  <result pre="trials and long-term extension studies in rheumatoid arthritis reveals serious" exact="infection" post="rates of 2.4 per 100 patient-years,42 comparable to the"/>
  <result pre="particular concern with JAK inhibition is the risk of varicella" exact="zoster" post="virus reactivation and antiviral immunity. This appears to be"/>
  <result pre="demonstrated antiviral activity via inhibition of receptor-mediated endocytosis of SARS-CoV-2" exact="viral" post="particles.50 Additional concerns in COVID-19 A high rate of"/>
  <result pre="viral particles.50 Additional concerns in COVID-19 A high rate of" exact="venous thromboembolism" post="(VTE) has been noted in COVID-19, occurring in up"/>
  <result pre="inhibitors is associated with an increased risk of serious infection," exact="herpes zoster" post="virus reactivation, and VTE. However, recent studies show potential"/>
  <result pre="is associated with an increased risk of serious infection, herpes" exact="zoster" post="virus reactivation, and VTE. However, recent studies show potential"/>
  <result pre="Diseases), a Spanish registry designed to study the safety of" exact="systemic" post="therapy in psoriasis, showed an increased risk of overall"/>
  <result pre="systemic therapy in psoriasis, showed an increased risk of overall" exact="infection" post="with tumor necrosis factor (TNF) inhibitors compared with ustekinumab"/>
  <result pre="in psoriasis, showed an increased risk of overall infection with" exact="tumor" post="necrosis factor (TNF) inhibitors compared with ustekinumab and nonbiologic"/>
  <result pre="Of all TNF inhibitors, infliximab had the highest risk of" exact="infection" post="(adjusted riskÂ ratio, 1.71; 95% CI, 1.1-2.65).54 Similarly, data"/>
  <result pre="Assessment and Registry (PSOLAR) indicated a higher risk of serious" exact="infections" post="with adalimumab and infliximab compared with nonbiologic drugs.55 Conversely,"/>
  <result pre="compared with nonbiologic drugs.55 Conversely, no increased risk of serious" exact="infections" post="was noted when ustekinumab and etanercept were compared with"/>
  <result pre="Murrell etÂ al56 reviewed data from pivotal clinical trials in" exact="psoriasis" post="and found that URIs were increased with TNF inhibitors"/>
  <result pre="clinical trial data for all 11 biologic therapies approved in" exact="psoriasis" post="and found no significant increase in URI or influenza"/>
  <result pre="psoriasis and found no significant increase in URI or influenza" exact="infection" post="rates compared with placebo.57 In contrast, Wan etÂ al58"/>
  <result pre="with 3 IL-17 inhibitors and found an increased risk of" exact="viral" post="and nonviral URIs compared with placebo (odds ratio [OR],"/>
  <result pre="Further data are needed regarding any potential increased risk of" exact="viral" post="and nonviral URIs associated with IL-17 inhibition. The data"/>
  <result pre="IL-17 inhibition. The data presented indicate higher rates of overall" exact="infection" post="and URIs with TNF inhibitors; however, ongoing trials investigating"/>
  <result pre="the safety of TNF inhibitors in COVID-19. Rituximab Reactivation of" exact="chronic" post="viral infections, such as hepatitis B and cytomegalovirus, is"/>
  <result pre="safety of TNF inhibitors in COVID-19. Rituximab Reactivation of chronic" exact="viral" post="infections, such as hepatitis B and cytomegalovirus, is a"/>
  <result pre="in COVID-19. Rituximab Reactivation of chronic viral infections, such as" exact="hepatitis" post="B and cytomegalovirus, is a rare yet well-reported adverse"/>
  <result pre="is a rare yet well-reported adverse effect of rituximab.59 Other" exact="viral" post="illnesses, such as URIs and nasopharyngitis, are frequently reported,"/>
  <result pre="and nasopharyngitis, are frequently reported, but clinical trial data in" exact="rheumatoid arthritis" post="suggest similar overall rates of infections when rituximab is"/>
  <result pre="nasopharyngitis, are frequently reported, but clinical trial data in rheumatoid" exact="arthritis" post="suggest similar overall rates of infections when rituximab is"/>
  <result pre="trial data in rheumatoid arthritis suggest similar overall rates of" exact="infections" post="when rituximab is compared with methotrexate plus placebo.60,61 Long-term"/>
  <result pre="placebo.60,61 Long-term observational studies also show that this risk remains" exact="stable" post="with repeated infusions.62,63 Data in the dermatologic literature are"/>
  <result pre="dermatologic literature are limited, but a randomized controlled trial in" exact="pemphigus" post="vulgaris showed a similar rate of infections in the"/>
  <result pre="controlled trial in pemphigus vulgaris showed a similar rate of" exact="infections" post="in the rituximab plus short-term steroid group compared with"/>
  <result pre="However, it is worth noting that the rituximab group had" exact="lower" post="cumulative exposure to prednisone. An important consideration is the"/>
  <result pre="the literature reveal an increased risk of URIs, pneumonias, and" exact="viral" post="infections, including fatal instances of enteroviral meningoencephalitis.66,67 Particular concerns"/>
  <result pre="treatment with rituximab.68,69 Conclusions The data suggest increased rates of" exact="infection" post="and infectious complications associated with the use of rituximab."/>
  <result pre="rituximab.68,69 Conclusions The data suggest increased rates of infection and" exact="infectious" post="complications associated with the use of rituximab. Together with"/>
  <result pre="pandemic. To minimize harm, evaluation (and potential correction) of rituximab-induced" exact="hypogammaglobulinemia" post="may be considered among patients who receive recurrent rituximab"/>
  <result pre="of rituximab-induced hypogammaglobulinemia may be considered among patients who receive" exact="recurrent" post="rituximab dosing. Dupilumab A comprehensive evaluation of infection risk"/>
  <result pre="who receive recurrent rituximab dosing. Dupilumab A comprehensive evaluation of" exact="infection" post="risk with dupilumab was conducted by Eichenfield etÂ al.70"/>
  <result pre="Their analysis pooled data from 7 randomized controlled trials in" exact="atopic dermatitis," post="which showed similar infection rates per 100 patient-years in"/>
  <result pre="7 randomized controlled trials in atopic dermatitis, which showed similar" exact="infection" post="rates per 100 patient-years in the treatment and placebo"/>
  <result pre="in the treatment and placebo groups. Specifically, the rates of" exact="viral" post="URIs and influenza infections were lower in the dupilumab"/>
  <result pre="placebo groups. Specifically, the rates of viral URIs and influenza" exact="infections" post="were lower in the dupilumab groups compared with placebo."/>
  <result pre="Specifically, the rates of viral URIs and influenza infections were" exact="lower" post="in the dupilumab groups compared with placebo. Similarly, an"/>
  <result pre="etÂ al32 found no increase in the rates of serious" exact="bacterial" post="or opportunistic infections with dupilumab compared with methotrexate. Conclusions"/>
  <result pre="found no increase in the rates of serious bacterial or" exact="opportunistic infections" post="with dupilumab compared with methotrexate. Conclusions Data to date"/>
  <result pre="no increase in the rates of serious bacterial or opportunistic" exact="infections" post="with dupilumab compared with methotrexate. Conclusions Data to date"/>
  <result pre="methotrexate. Conclusions Data to date suggest a low risk of" exact="infection" post="with the use of dupilumab and a low potential"/>
  <result pre="large case series and 2 registries have reported a combined" exact="total" post="of 721 confirmed or highly suspected cases of COVID-19"/>
  <result pre="of 721 confirmed or highly suspected cases of COVID-19 in" exact="adult" post="and pediatric immune-mediated inflammatory disease populations through May 19,"/>
  <result pre="suspected cases of COVID-19 in adult and pediatric immune-mediated inflammatory" exact="disease" post="populations through May 19, 2020.71, 72, 73 The results"/>
  <result pre="noted that those requiring hospitalization were more likely to have" exact="rheumatoid arthritis," post="had more comorbidities, were older, and had greater use"/>
  <result pre="II Summary of large case series and registry data of" exact="autoimmune disease" post="patients infected or exposed to SARS-CoV-2 Characteristicsâˆ— Studies Haberman"/>
  <result pre="Summary of large case series and registry data of autoimmune" exact="disease" post="patients infected or exposed to SARS-CoV-2 Characteristicsâˆ— Studies Haberman"/>
  <result pre="Studies Haberman etÂ al71 Gianfrancesco etÂ al72 Brenner etÂ al73" exact="Total" post="number of patientsâ€ 86 110 525 Confirmed cases of"/>
  <result pre="110 (100) 525 (100) Age, mean y 46 N/Aâ€¡ 43" exact="Female" post="sex 49 (57) 79 (72) 243 (46.3) Most common"/>
  <result pre="1 (1) 6 (5) 16 (3) AS, Ankylosing spondylitis; CD," exact="Crohn's disease;" post="COVID-19, coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic"/>
  <result pre="16 (3) AS, Ankylosing spondylitis; CD, Crohn's disease; COVID-19, coronavirus" exact="disease" post="2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD, inflammatory"/>
  <result pre="coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD," exact="inflammatory bowel disease;" post="IL, interleukin; JAK, Janus kinase inhibitor; MTX, methotrexate; N/A,"/>
  <result pre="disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IBD, inflammatory" exact="bowel" post="disease; IL, interleukin; JAK, Janus kinase inhibitor; MTX, methotrexate;"/>
  <result pre="JAK, Janus kinase inhibitor; MTX, methotrexate; N/A, not available; PsA," exact="psoriatic arthritis;" post="RA, rheumatoid arthritis; SARS-Cov-2, severe acute respiratory syndrome coronavirus"/>
  <result pre="inhibitor; MTX, methotrexate; N/A, not available; PsA, psoriatic arthritis; RA," exact="rheumatoid arthritis;" post="SARS-Cov-2, severe acute respiratory syndrome coronavirus 2; SjS, SjÃ¶gren"/>
  <result pre="not available; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SARS-Cov-2, severe" exact="acute" post="respiratory syndrome coronavirus 2; SjS, SjÃ¶gren syndrome; SLE, systemic"/>
  <result pre="available; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SARS-Cov-2, severe acute" exact="respiratory" post="syndrome coronavirus 2; SjS, SjÃ¶gren syndrome; SLE, systemic lupus"/>
  <result pre="PsA, psoriatic arthritis; RA, rheumatoid arthritis; SARS-Cov-2, severe acute respiratory" exact="syndrome" post="coronavirus 2; SjS, SjÃ¶gren syndrome; SLE, systemic lupus erythematosus;"/>
  <result pre="severe acute respiratory syndrome coronavirus 2; SjS, SjÃ¶gren syndrome; SLE," exact="systemic" post="lupus erythematosus; TNFi, tumor necrosis factor-Î± inhibitor; UC, ulcerative"/>
  <result pre="acute respiratory syndrome coronavirus 2; SjS, SjÃ¶gren syndrome; SLE, systemic" exact="lupus erythematosus;" post="TNFi, tumor necrosis factor-Î± inhibitor; UC, ulcerative colitis. âˆ—Data"/>
  <result pre="coronavirus 2; SjS, SjÃ¶gren syndrome; SLE, systemic lupus erythematosus; TNFi," exact="tumor" post="necrosis factor-Î± inhibitor; UC, ulcerative colitis. âˆ—Data are shown"/>
  <result pre="SLE, systemic lupus erythematosus; TNFi, tumor necrosis factor-Î± inhibitor; UC," exact="ulcerative colitis." post="âˆ—Data are shown as number (%) or as indicated"/>
  <result pre="aged &amp;gt;65Â years. Â§Other included (all with nÂ In the" exact="inflammatory bowel disease" post="registry, 16 deaths (3%) were identified, with half occurring"/>
  <result pre="&amp;gt;65Â years. Â§Other included (all with nÂ In the inflammatory" exact="bowel" post="disease registry, 16 deaths (3%) were identified, with half"/>
  <result pre="years. Â§Other included (all with nÂ In the inflammatory bowel" exact="disease" post="registry, 16 deaths (3%) were identified, with half occurring"/>
  <result pre="multivariate analysis, Brenner etÂ al73 reported a strong association between" exact="systemic" post="steroids and the composite outcome of intensive care unit"/>
  <result pre="of 112) of patients on IL-12/23 inhibitors. With regards to" exact="infection" post="risk, a case-control study by Damiani etÂ al74 evaluated"/>
  <result pre="case-control study by Damiani etÂ al74 evaluated 1193 patients with" exact="psoriasis" post="and identified only 16 cases of COVID-19 from February"/>
  <result pre="3.59; 95% CI, 1.49-8.63). Conclusion Most of the patients on" exact="systemic" post="immunosuppressive or immunomodulatory therapy included in these studies did"/>
  <result pre="not require hospitalization, and death remained a rare outcome. However," exact="systemic" post="corticosteroid use in this patient population appeared to increase"/>
  <result pre="III Guidance statements for management of immunosuppression during the coronavirus" exact="disease" post="2019 (COVID-19) pandemicâˆ— Patients well-controlled on maintenance therapy We"/>
  <result pre="predict poor COVID-19 outcomes.We do note the following exceptions: a.Long-term" exact="systemic" post="steroids should be tapered to daily doses &amp;lt;10Â mg"/>
  <result pre="mg prednisone equivalent, if safe to do so. b.Patients on" exact="recurrent" post="rituximab dosing may benefit from immunoglobulin level testing. If"/>
  <result pre="recurrent rituximab dosing may benefit from immunoglobulin level testing. If" exact="hypogammaglobulinemia" post="exists, consider altering/delaying dose or initiating immunoglobulin therapy, or"/>
  <result pre="of treatment We suggest the following: a.On the basis of" exact="disease" post="severity and baseline risk, consider favoring low-risk immunomodulatory agents"/>
  <result pre="immunosuppressive agents with a higher known or suspected risk of" exact="infection" post="(see Table II). b.When medically appropriate, opt for short"/>
  <result pre="of infection (see Table II). b.When medically appropriate, opt for" exact="short" post="courses of low to moderate doses of systemic corticosteroids"/>
  <result pre="opt for short courses of low to moderate doses of" exact="systemic" post="corticosteroids over high-dose regimens (eg, &amp;lt;20Â mg prednisone equivalent"/>
  <result pre="with active COVID-19 infection, including COVID-19+ testing (even in the" exact="absence of" post="symptoms) Although the potential benefit of immunosuppression is being"/>
  <result pre="even if asymptomatic, with the concern being the complication of" exact="bacterial infections" post="and pneumonia. Many systemic immunosuppressive drugs have long half-lives,"/>
  <result pre="if asymptomatic, with the concern being the complication of bacterial" exact="infections" post="and pneumonia. Many systemic immunosuppressive drugs have long half-lives,"/>
  <result pre="concern being the complication of bacterial infections and pneumonia. Many" exact="systemic" post="immunosuppressive drugs have long half-lives, and temporary cessation of"/>
  <result pre="and temporary cessation of therapy is unlikely to result in" exact="disease" post="flare. Individual discussions may be considered for severe flares"/>
  <result pre="manifestations. Treatment can resume after recovery (refer to Centers for" exact="Disease" post="Control and Prevention or local health authority for recovery"/>
  <result pre="patient assessment (refer to Table I). Patients with active immune-mediated" exact="skin disease" post="a.When possible, maximize/optimize nonimmunosuppressive therapy, such as topical steroids,"/>
  <result pre="assessment (refer to Table I). Patients with active immune-mediated skin" exact="disease" post="a.When possible, maximize/optimize nonimmunosuppressive therapy, such as topical steroids,"/>
  <result pre="and anti-inflammatory medications (eg, tetracycline or macrolide class antibiotics). b.High-dose" exact="systemic" post="corticosteroids should be avoided where possible, and taper plans"/>
  <result pre="be kept to the minimum necessary dose and duration. âˆ—With" exact="limited" post="COVID-specific safety data available on any given treatment, it"/>
  <result pre="Limitations include the heterogeneity of the safety data encompassing various" exact="autoimmune" post="conditions and the limited reports available on the status"/>
  <result pre="of the safety data encompassing various autoimmune conditions and the" exact="limited" post="reports available on the status of immunosuppressed patients affected"/>
  <result pre="The applicability of the information and recommendations provided here are" exact="limited" post="by the rapidly evolving nature of the COVID-19 pandemic,"/>
  <result pre="1 Drug safety recommendations in the context of the coronavirus" exact="disease" post="2019 (COVID-19) pandemic. CMV, Cytomegalovirus; DVT, deep venous thrombosis;"/>
  <result pre="of the coronavirus disease 2019 (COVID-19) pandemic. CMV, Cytomegalovirus; DVT," exact="deep venous thrombosis;" post="HZV, herpes zoster virus; IL, interleukin; PE, pulmonary embolus;"/>
  <result pre="2019 (COVID-19) pandemic. CMV, Cytomegalovirus; DVT, deep venous thrombosis; HZV," exact="herpes zoster" post="virus; IL, interleukin; PE, pulmonary embolus; URI, upper respiratory"/>
  <result pre="(COVID-19) pandemic. CMV, Cytomegalovirus; DVT, deep venous thrombosis; HZV, herpes" exact="zoster" post="virus; IL, interleukin; PE, pulmonary embolus; URI, upper respiratory"/>
  <result pre="deep venous thrombosis; HZV, herpes zoster virus; IL, interleukin; PE," exact="pulmonary embolus;" post="URI, upper respiratory infection. Further data regarding the safety"/>
  <result pre="HZV, herpes zoster virus; IL, interleukin; PE, pulmonary embolus; URI," exact="upper respiratory infection." post="Further data regarding the safety of these agents are"/>
  <result pre="herpes zoster virus; IL, interleukin; PE, pulmonary embolus; URI, upper" exact="respiratory" post="infection. Further data regarding the safety of these agents"/>
  <result pre="our patients. References References 1WakkeeM.de VriesE.van den HaakP.NijstenT.Increased risk of" exact="infectious disease" post="requiring hospitalization among patients with psoriasis: a population-based cohortJ"/>
  <result pre="patients. References References 1WakkeeM.de VriesE.van den HaakP.NijstenT.Increased risk of infectious" exact="disease" post="requiring hospitalization among patients with psoriasis: a population-based cohortJ"/>
  <result pre="psoriasis: a population-based cohortJ Am Acad Dermatol65620111135114421664719 2HerrintonL.J.LiuL.GoldfienR.MichaelsM.A.TranT.N.Risk of serious" exact="infection" post="for patients with systemic lupus erythematosus starting glucocorticoids with"/>
  <result pre="Am Acad Dermatol65620111135114421664719 2HerrintonL.J.LiuL.GoldfienR.MichaelsM.A.TranT.N.Risk of serious infection for patients with" exact="systemic" post="lupus erythematosus starting glucocorticoids with or without antimalarialsJ Rheumatol43820161503150927370880"/>
  <result pre="Acad Dermatol65620111135114421664719 2HerrintonL.J.LiuL.GoldfienR.MichaelsM.A.TranT.N.Risk of serious infection for patients with systemic" exact="lupus erythematosus" post="starting glucocorticoids with or without antimalarialsJ Rheumatol43820161503150927370880 3Perez-ChadaL.M.MerolaJ.F.Comorbidities associated"/>
  <result pre="4WangD.HuB.HuC.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA32311202010611069 5HuiD.S.AzharE.I.KimY.-J.MemishZ.A.OhM.ZumlaA.Middle East respiratory syndrome coronavirus: risk"/>
  <result pre="with 2019 novel coronavirus-infected pneumonia in Wuhan, ChinaJAMA32311202010611069 5HuiD.S.AzharE.I.KimY.-J.MemishZ.A.OhM.ZumlaA.Middle East" exact="respiratory" post="syndrome coronavirus: risk factors and determinants of primary, household,"/>
  <result pre="2019 novel coronavirus-infected pneumonia in Wuhan, ChinaJAMA32311202010611069 5HuiD.S.AzharE.I.KimY.-J.MemishZ.A.OhM.ZumlaA.Middle East respiratory" exact="syndrome" post="coronavirus: risk factors and determinants of primary, household, and"/>
  <result pre="during the third epidemicLiver Transpl266202083283432196933 7LamM.-F.OoiG.C.LamB.An indolent case of severe" exact="acute" post="respiratory syndromeAm J Respir Crit Care Med1691200412512814695107 8KimS.-H.KoJ.-H.ParkG.E.Atypical presentations"/>
  <result pre="the third epidemicLiver Transpl266202083283432196933 7LamM.-F.OoiG.C.LamB.An indolent case of severe acute" exact="respiratory" post="syndromeAm J Respir Crit Care Med1691200412512814695107 8KimS.-H.KoJ.-H.ParkG.E.Atypical presentations of"/>
  <result pre="syndromeAm J Respir Crit Care Med1691200412512814695107 8KimS.-H.KoJ.-H.ParkG.E.Atypical presentations of MERS-CoV" exact="infection" post="in immunocompromised hostsJ Infect Chemother2311201776977328545936 9PrescottJ.FalzaranoD.de WitE.Pathogenicity and viral"/>
  <result pre="MERS-CoV infection in immunocompromised hostsJ Infect Chemother2311201776977328545936 9PrescottJ.FalzaranoD.de WitE.Pathogenicity and" exact="viral" post="shedding of MERS-CoV in immunocompromised rhesus macaquesFront Immunol9201820529483914 10MeradM.MartinJ.C.Pathological"/>
  <result pre="key role for monocytes and macrophagesNat Rev Immunol206202035536232376901 11StuckA.E.MinderC.E.FreyF.J.Risk of" exact="infectious" post="complications in patients taking glucocorticosteroidsRev Infect Dis11619899549632690289 12MigitaK.SasakiY.IshizukaN.Glucocorticoid therapy"/>
  <result pre="taking glucocorticosteroidsRev Infect Dis11619899549632690289 12MigitaK.SasakiY.IshizukaN.Glucocorticoid therapy and the risk of" exact="infection" post="in patients with newly diagnosed autoimmune diseaseMedicine (Baltimore)925201328529323982055 13GreenbergJ.D.ReedG.KremerJ.M.Association"/>
  <result pre="and the risk of infection in patients with newly diagnosed" exact="autoimmune" post="diseaseMedicine (Baltimore)925201328529323982055 13GreenbergJ.D.ReedG.KremerJ.M.Association of methotrexate and tumour necrosis factor"/>
  <result pre="of methotrexate and tumour necrosis factor antagonists with risk of" exact="infectious" post="outcomes including opportunistic infections in the CORRONA registryAnn Rheum"/>
  <result pre="tumour necrosis factor antagonists with risk of infectious outcomes including" exact="opportunistic infections" post="in the CORRONA registryAnn Rheum Dis692201038038619359261 14Horby P, Lim"/>
  <result pre="necrosis factor antagonists with risk of infectious outcomes including opportunistic" exact="infections" post="in the CORRONA registryAnn Rheum Dis692201038038619359261 14Horby P, Lim"/>
  <result pre="early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in" exact="adult" post="patientsJ Clin Virol314200430430915494274 16HuiD.S.Systemic corticosteroid therapy may delay viral"/>
  <result pre="in adult patientsJ Clin Virol314200430430915494274 16HuiD.S.Systemic corticosteroid therapy may delay" exact="viral" post="clearance in patients with Middle East respiratory syndrome coronavirus"/>
  <result pre="therapy may delay viral clearance in patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionAm J Respir Crit Care Med19762017700701 17ArabiY.M.MandourahY.Al-HameedF.Corticosteroid"/>
  <result pre="may delay viral clearance in patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionAm J Respir Crit Care Med19762017700701 17ArabiY.M.MandourahY.Al-HameedF.Corticosteroid therapy"/>
  <result pre="Med19762017700701 17ArabiY.M.MandourahY.Al-HameedF.Corticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndromeAm J Respir Crit Care Med19762017757767 18LansburyL.RodrigoC.Leonardi-BeeJ.Nguyen-Van-TamJ.LimW.S.Corticosteroids as adjunctive"/>
  <result pre="influenza pneumonia: a systematic review and meta-analysisCrit Care23120199930917856 20IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
  <result pre="Intern Med1726202036938032066146 22Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM.A.Clinical efficacy and side effects of antimalarials in" exact="systemic" post="lupus erythematosus: a systematic reviewAnn Rheum Dis69012010202819103632 23BernatskyS.HudsonM.SuissaS.Anti-rheumatic drug"/>
  <result pre="Med1726202036938032066146 22Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM.A.Clinical efficacy and side effects of antimalarials in systemic" exact="lupus" post="erythematosus: a systematic reviewAnn Rheum Dis69012010202819103632 23BernatskyS.HudsonM.SuissaS.Anti-rheumatic drug use"/>
  <result pre="reviewAnn Rheum Dis69012010202819103632 23BernatskyS.HudsonM.SuissaS.Anti-rheumatic drug use and risk of serious" exact="infections" post="in rheumatoid arthritisRheumatology (Oxford)46720071157116017478469 24YaoX.YeF.ZhangM.InÂ vitro antiviral activity and"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [e-pub ahead of print]Clin"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [e-pub ahead of print]Clin Infect"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [e-pub ahead of print]Clin Infect Dis202010.1093/cid/ciaa237"/>
  <result pre="ahead of print]Clin Infect Dis202010.1093/cid/ciaa237 25KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.InÂ vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review:"/>
  <result pre="of print]Clin Infect Dis202010.1093/cid/ciaa237 25KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.InÂ vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review: hydroxychloroquine"/>
  <result pre="print]Clin Infect Dis202010.1093/cid/ciaa237 25KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.InÂ vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review: hydroxychloroquine and"/>
  <result pre="of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19" exact="infection" post="with oxygen requirement: results of a study using routinely"/>
  <result pre="[preprint]medRxiv202010.1101/2020.04.16.20065920 30TangW.CaoZ.HanM.Hydroxychloroquine in patients mainly with mild to moderate coronavirus" exact="disease" post="2019: an open-label, randomized, controlled trialBMJ3692020m184932409561 31US Food and"/>
  <result pre="hospital setting or a clinical trial due to risk of" exact="heart" post="rhythm problems: does not affect FDA-approved uses for malaria,"/>
  <result pre="for malaria, lupus, and rheumatoid arthritisAvailable at:https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or2020 32SchneeweissM.C.Perez-ChadaL.MerolaJ.F.Comparative safety of" exact="systemic" post="immuno-modulatory medications in adults with atopic dermatitis [e-pub ahead"/>
  <result pre="at:https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or2020 32SchneeweissM.C.Perez-ChadaL.MerolaJ.F.Comparative safety of systemic immuno-modulatory medications in adults with" exact="atopic dermatitis" post="[e-pub ahead of print]J Am Acad Dermatol201910.1016/j.jaad.2019.05.073 33FeldmanC.H.MartyF.M.WinkelmayerW.C.Comparative rates"/>
  <result pre="32SchneeweissM.C.Perez-ChadaL.MerolaJ.F.Comparative safety of systemic immuno-modulatory medications in adults with atopic" exact="dermatitis" post="[e-pub ahead of print]J Am Acad Dermatol201910.1016/j.jaad.2019.05.073 33FeldmanC.H.MartyF.M.WinkelmayerW.C.Comparative rates"/>
  <result pre="ahead of print]J Am Acad Dermatol201910.1016/j.jaad.2019.05.073 33FeldmanC.H.MartyF.M.WinkelmayerW.C.Comparative rates of serious" exact="infections" post="among patients with systemic lupus erythematosus receiving immunosuppressive medicationsArthritis"/>
  <result pre="Acad Dermatol201910.1016/j.jaad.2019.05.073 33FeldmanC.H.MartyF.M.WinkelmayerW.C.Comparative rates of serious infections among patients with" exact="systemic" post="lupus erythematosus receiving immunosuppressive medicationsArthritis Rheumatol692201738739727589220 34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of"/>
  <result pre="Dermatol201910.1016/j.jaad.2019.05.073 33FeldmanC.H.MartyF.M.WinkelmayerW.C.Comparative rates of serious infections among patients with systemic" exact="lupus erythematosus" post="receiving immunosuppressive medicationsArthritis Rheumatol692201738739727589220 34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of systemic serious"/>
  <result pre="systemic lupus erythematosus receiving immunosuppressive medicationsArthritis Rheumatol692201738739727589220 34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of" exact="systemic" post="serious viral infections in patients with inflammatory bowel disease"/>
  <result pre="erythematosus receiving immunosuppressive medicationsArthritis Rheumatol692201738739727589220 34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of systemic serious" exact="viral" post="infections in patients with inflammatory bowel disease associates with"/>
  <result pre="receiving immunosuppressive medicationsArthritis Rheumatol692201738739727589220 34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of systemic serious viral" exact="infections" post="in patients with inflammatory bowel disease associates with active"/>
  <result pre="34WisniewskiA.KirchgesnerJ.SeksikP.Increased incidence of systemic serious viral infections in patients with" exact="inflammatory bowel disease" post="associates with active disease and use of thiopurinesUnited European"/>
  <result pre="incidence of systemic serious viral infections in patients with inflammatory" exact="bowel" post="disease associates with active disease and use of thiopurinesUnited"/>
  <result pre="of systemic serious viral infections in patients with inflammatory bowel" exact="disease" post="associates with active disease and use of thiopurinesUnited European"/>
  <result pre="infections in patients with inflammatory bowel disease associates with active" exact="disease" post="and use of thiopurinesUnited European Gastroenterol J832020303313 35WolfeF.MichaudK.ChakravartyE.F.Rates and"/>
  <result pre="use of thiopurinesUnited European Gastroenterol J832020303313 35WolfeF.MichaudK.ChakravartyE.F.Rates and predictors of" exact="herpes zoster" post="in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disordersRheumatology"/>
  <result pre="of thiopurinesUnited European Gastroenterol J832020303313 35WolfeF.MichaudK.ChakravartyE.F.Rates and predictors of herpes" exact="zoster" post="in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disordersRheumatology"/>
  <result pre="J832020303313 35WolfeF.MichaudK.ChakravartyE.F.Rates and predictors of herpes zoster in patients with" exact="rheumatoid arthritis" post="and non-inflammatory musculoskeletal disordersRheumatology (Oxford)451120061370137517003175 36collab: The Tricontinental Mycophenolate"/>
  <result pre="35WolfeF.MichaudK.ChakravartyE.F.Rates and predictors of herpes zoster in patients with rheumatoid" exact="arthritis" post="and non-inflammatory musculoskeletal disordersRheumatology (Oxford)451120061370137517003175 36collab: The Tricontinental Mycophenolate"/>
  <result pre="and non-inflammatory musculoskeletal disordersRheumatology (Oxford)451120061370137517003175 36collab: The Tricontinental Mycophenolate Mofetil" exact="Renal" post="Transplantation Study GroupA blinded, randomized clinical trial of mycophenolate"/>
  <result pre="randomized clinical trial of mycophenolate mofetil for the prevention of" exact="acute" post="rejection in cadaveric renal transplantationTransplantation6171996102910378623181 37CourM.OvizeM.ArgaudL.Cyclosporine A: a valid"/>
  <result pre="37CourM.OvizeM.ArgaudL.Cyclosporine A: a valid candidate to treat COVID-19 patients with" exact="acute" post="respiratory failure?Crit Care241202027632487139 38de WildeA.H.Zevenhoven-DobbeJ.C.van der MeerY.Cyclosporin A inhibits"/>
  <result pre="A: a valid candidate to treat COVID-19 patients with acute" exact="respiratory" post="failure?Crit Care241202027632487139 38de WildeA.H.Zevenhoven-DobbeJ.C.van der MeerY.Cyclosporin A inhibits the"/>
  <result pre="Res Ther21120198930953540 43VieiraM.-C.ZwillichS.H.JansenJ.P.SmiechowskiB.SpurdenD.WallensteinG.V.Tofacitinib versus biologic treatments in patients with active" exact="rheumatoid arthritis" post="who have had an inadequate response to tumor necrosis"/>
  <result pre="Ther21120198930953540 43VieiraM.-C.ZwillichS.H.JansenJ.P.SmiechowskiB.SpurdenD.WallensteinG.V.Tofacitinib versus biologic treatments in patients with active rheumatoid" exact="arthritis" post="who have had an inadequate response to tumor necrosis"/>
  <result pre="active rheumatoid arthritis who have had an inadequate response to" exact="tumor" post="necrosis factor inhibitors: results from a network meta-analysisClin Ther3812201626282641.e527889300"/>
  <result pre="results from a network meta-analysisClin Ther3812201626282641.e527889300 44StrandV.AhadiehS.DeMasiR.THU0211 Meta-analysis of serious" exact="infections" post="with baricitinib, tofacitinib and biologic DMARDs in rheumatoid arthritis"/>
  <result pre="of serious infections with baricitinib, tofacitinib and biologic DMARDs in" exact="rheumatoid arthritis" post="[abstract]Ann Rheum Dis76Suppl 22017284 45SmolenJ.S.GenoveseM.C.TakeuchiT.Safety profile of baricitinib in"/>
  <result pre="serious infections with baricitinib, tofacitinib and biologic DMARDs in rheumatoid" exact="arthritis" post="[abstract]Ann Rheum Dis76Suppl 22017284 45SmolenJ.S.GenoveseM.C.TakeuchiT.Safety profile of baricitinib in"/>
  <result pre="Dis76Suppl 22017284 45SmolenJ.S.GenoveseM.C.TakeuchiT.Safety profile of baricitinib in patients with active" exact="rheumatoid arthritis" post="with over 2 years median time in treatmentJ Rheumatol461201971830219772"/>
  <result pre="22017284 45SmolenJ.S.GenoveseM.C.TakeuchiT.Safety profile of baricitinib in patients with active rheumatoid" exact="arthritis" post="with over 2 years median time in treatmentJ Rheumatol461201971830219772"/>
  <result pre="with over 2 years median time in treatmentJ Rheumatol461201971830219772 46WinthropK.L.CurtisJ.R.LindseyS.Herpes" exact="zoster" post="and tofacitinib: clinical outcomes and the risk of concomitant"/>
  <result pre="therapyArthritis Rheumatol691020171960196828845604 47OliveraP.A.LasaJ.S.BonovasS.DaneseS.Peyrin-BirouletL.Safety of Janus kinase inhibitors in patients with" exact="inflammatory bowel diseases" post="or other immune-mediated diseases: a systematic review and meta-analysisGastroenterology1586202015541573.e1231926171"/>
  <result pre="Rheumatol691020171960196828845604 47OliveraP.A.LasaJ.S.BonovasS.DaneseS.Peyrin-BirouletL.Safety of Janus kinase inhibitors in patients with inflammatory" exact="bowel" post="diseases or other immune-mediated diseases: a systematic review and"/>
  <result pre="or other immune-mediated diseases: a systematic review and meta-analysisGastroenterology1586202015541573.e1231926171 48WinthropK.L.LebwohlM.CohenA.D.Herpes" exact="zoster" post="in psoriasis patients treated with tofacitinibJ Am Acad Dermatol772201730230928711084"/>
  <result pre="immune-mediated diseases: a systematic review and meta-analysisGastroenterology1586202015541573.e1231926171 48WinthropK.L.LebwohlM.CohenA.D.Herpes zoster in" exact="psoriasis" post="patients treated with tofacitinibJ Am Acad Dermatol772201730230928711084 49McGonagleD.SharifK.O'ReganA.BridgewoodC.The role"/>
  <result pre="Dermatol772201730230928711084 49McGonagleD.SharifK.O'ReganA.BridgewoodC.The role of cytokines including interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like diseaseAutoimmun Rev196202010253732251717 50StebbingJ.PhelanA.GriffinI.COVID-19: combining antiviral"/>
  <result pre="combining antiviral and anti-inflammatory treatmentsLancet Infect Dis204202040040232113509 51WichmannD.SperhakeJ.-P.LÃ¼tgehetmannM.Autopsy findings and" exact="venous thromboembolism" post="in patients with COVID-19: a prospective cohort study [e-pub"/>
  <result pre="systematic literature reviewsAnn Rheum Dis796202067968032033940 54DÃ¡vila-SeijoP.DaudenE.DescalzoM.A.Infections in moderate to severe" exact="psoriasis" post="patients treated with biological drugs compared to classic systemic"/>
  <result pre="severe psoriasis patients treated with biological drugs compared to classic" exact="systemic" post="drugs: findings from the BIOBADADERM RegistryJ Investig Dermatol1372201731332127677836 55KalbR.E.FiorentinoD.F.LebwohlM.G.Risk"/>
  <result pre="findings from the BIOBADADERM RegistryJ Investig Dermatol1372201731332127677836 55KalbR.E.FiorentinoD.F.LebwohlM.G.Risk of serious" exact="infection" post="with biologic and systemic treatment of psoriasis: results from"/>
  <result pre="RegistryJ Investig Dermatol1372201731332127677836 55KalbR.E.FiorentinoD.F.LebwohlM.G.Risk of serious infection with biologic and" exact="systemic" post="treatment of psoriasis: results from the Psoriasis Longitudinal Assessment"/>
  <result pre="Psoriasis Longitudinal Assessment and Registry (PSOLAR)JAMA Dermatol1519201596196925970800 56LebwohlM.Rivera-OyolaR.MurrellD.F.Should biologics for" exact="psoriasis" post="be interrupted in the era of COVID-19?J Am Acad"/>
  <result pre="in the era of COVID-19?J Am Acad Dermatol82520201217121832199889 57BrownstoneN.D.ThibodeauxQ.G.ReddyV.D.Novel coronavirus" exact="disease" post="(COVID-19) and biologic therapy in psoriasis: infection risk and"/>
  <result pre="Dermatol82520201217121832199889 57BrownstoneN.D.ThibodeauxQ.G.ReddyV.D.Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis:" exact="infection" post="risk and patient counseling in uncertain timesDermatol Ther (Heidelb)102020339349"/>
  <result pre="MT, Shin DB, Winthrop KL, Gelfand JM. The risk of" exact="respiratory" post="tract infections and symptoms in psoriasis patients treated with"/>
  <result pre="DB, Winthrop KL, Gelfand JM. The risk of respiratory tract" exact="infections" post="and symptoms in psoriasis patients treated with interleukin 17â€&quot;pathway"/>
  <result pre="JM. The risk of respiratory tract infections and symptoms in" exact="psoriasis" post="patients treated with interleukin 17â€&quot;pathway inhibiting biologics: a meta-estimate"/>
  <result pre="Am Acad Dermatol. 2020. 10.1016/j.jaad.2020.05.035. Accessed May 19, 2020. 59AksoyS.HarputluogluH.KilickapS.Rituximab-related" exact="viral" post="infections in lymphoma patientsLeuk Lymphoma48720071307131217613758 60EmeryP.DeodharA.RigbyW.F.Efficacy and safety of"/>
  <result pre="Acad Dermatol. 2020. 10.1016/j.jaad.2020.05.035. Accessed May 19, 2020. 59AksoyS.HarputluogluH.KilickapS.Rituximab-related viral" exact="infections" post="in lymphoma patientsLeuk Lymphoma48720071307131217613758 60EmeryP.DeodharA.RigbyW.F.Efficacy and safety of different"/>
  <result pre="2020. 10.1016/j.jaad.2020.05.035. Accessed May 19, 2020. 59AksoyS.HarputluogluH.KilickapS.Rituximab-related viral infections in" exact="lymphoma" post="patientsLeuk Lymphoma48720071307131217613758 60EmeryP.DeodharA.RigbyW.F.Efficacy and safety of different doses and"/>
  <result pre="placebo-controlled trial in patients who are biological naÃ¯ve with active" exact="rheumatoid arthritis" post="and an inadequate response to methotrexate (Study Evaluating Rituximab's"/>
  <result pre="trial in patients who are biological naÃ¯ve with active rheumatoid" exact="arthritis" post="and an inadequate response to methotrexate (Study Evaluating Rituximab's"/>
  <result pre="Rheum Dis69920101629163520488885 61MeaseP.J.CohenS.GaylisN.B.Efficacy and safety of retreatment in patients with" exact="rheumatoid arthritis" post="with previous inadequate response to tumor necrosis factor inhibitors:"/>
  <result pre="Dis69920101629163520488885 61MeaseP.J.CohenS.GaylisN.B.Efficacy and safety of retreatment in patients with rheumatoid" exact="arthritis" post="with previous inadequate response to tumor necrosis factor inhibitors:"/>
  <result pre="in patients with rheumatoid arthritis with previous inadequate response to" exact="tumor" post="necrosis factor inhibitors: results from the SUNRISE TrialJ Rheumatol375201091792720194448"/>
  <result pre="62van VollenhovenR.F.FleischmannR.M.FurstD.E.LaceyS.LehaneP.B.Longterm safety of rituximab: final report of the Rheumatoid" exact="Arthritis" post="Global Clinical Trial Program over 11 yearsJ Rheumatol421020151761176626276965 63WinthropK.L.SaagK.CascinoM.D.Long-term"/>
  <result pre="with short-term prednisone versus prednisone alone for the treatment of" exact="pemphigus" post="(Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialLancet3891008320172031204028342637"/>
  <result pre="multicentre, parallel-group, open-label randomised trialLancet3891008320172031204028342637 65CooperN.DaviesE.G.ThrasherA.J.Repeated courses of rituximab for" exact="autoimmune" post="cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulinBr"/>
  <result pre="profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulinBr J Haematol1461200912012219438506 66CasuloC.MaraguliaJ.ZelenetzA.D.Incidence of" exact="hypogammaglobulinemia" post="in patients receiving rituximab and the use of intravenous"/>
  <result pre="patients receiving rituximab and the use of intravenous immunoglobulin for" exact="recurrent" post="infectionsClin Lymphoma Myeloma Leuk132201310611123276889 67MakatsoriM.Kiani-AlikhanS.MansonA.L.Hypogammaglobulinaemia after rituximab treatmentâ€&quot;incidence and"/>
  <result pre="rituximab and the use of intravenous immunoglobulin for recurrent infectionsClin" exact="Lymphoma" post="Myeloma Leuk132201310611123276889 67MakatsoriM.Kiani-AlikhanS.MansonA.L.Hypogammaglobulinaemia after rituximab treatmentâ€&quot;incidence and outcomesQJM10710201482182824778295 68van"/>
  <result pre="and the use of intravenous immunoglobulin for recurrent infectionsClin Lymphoma" exact="Myeloma" post="Leuk132201310611123276889 67MakatsoriM.Kiani-AlikhanS.MansonA.L.Hypogammaglobulinaemia after rituximab treatmentâ€&quot;incidence and outcomesQJM10710201482182824778295 68van AssenS.HolvastA.BenneC.A.Humoral"/>
  <result pre="responses after influenza vaccination are severely reduced in patients with" exact="rheumatoid arthritis" post="treated with rituximabArthritis Rheum6212010758120039396 69NaziI.KeltonJ.G.LarchÃ©M.The effect of rituximab on"/>
  <result pre="after influenza vaccination are severely reduced in patients with rheumatoid" exact="arthritis" post="treated with rituximabArthritis Rheum6212010758120039396 69NaziI.KeltonJ.G.LarchÃ©M.The effect of rituximab on"/>
  <result pre="New York [e-pub ahead of print]N Engl J Med202010.1056/NEJMc2009567 72GianfrancescoM.A.HyrichK.L.GossecL.Rheumatic" exact="disease" post="and COVID-19: initial data from the COVID-19 Global Rheumatology"/>
  <result pre="are associated with adverse COVID-19 outcomes in patients with inflammatory" exact="bowel" post="diseases: results from an international registry [e-pub ahead of"/>
  <result pre="[e-pub ahead of print]Gastroenterology202010.1053/j.gastro.2020.05.032 74DamianiG.PacificoA.BragazziN.L.MalagoliP.Biologics increase the risk of SARS-CoV-2" exact="infection" post="and hospitalization, but not ICU admission and death: real-life"/>
 </snippets>
</snippetsTree>
